The Defense Biological Product Assurance Office (DBPAO), a component of the Joint Program Executive Office for Chemical and Biological Defense, has announced the development of a Biological Select Agents and Toxins (BSAT) [Read more]
The Defense Threat Reduction Agency Joint Science and Technology Office’s (JSTO) Toxicant Penetration and Scavenging (TPS) research program, managed by Brian Pate, Ph.D., explores countermeasure development for increased protection against chemical and biological weapons. [Read more]
A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at sites in the United States. The Phase 1/2 trial, which is sponsored [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) has announced intentions to award a research and development contract to Evolva in support of a “Novel Toxicant and Repellent for Arthropod-borne Virus Vectors (NTRAVV)”. [Read more]
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Virology Division, Pathogenesis and Immunology Branch has been tasked by the Defense Threat Reduction Agency to investigate a potential for enhanced efficacy [Read more]
The U.S. Army Medical Research and Materiel Command (USAMRMC) Special Immunizations Program (SIP) currently offers Investigational New Drug (IND) products to both military and civilian personnel at risk for pathogen and toxin exposure. [Read more]
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded $46.6 million in [Read more]
Emergent BioSolutions Inc. held a ribbon-cutting ceremony last week on May 10 to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore. [Read more]
A pilot study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of an investigational medical countermeasure for Acute Radiation Syndrome (ARS) has shown promising results. ARS occurs following acute [Read more]
When the Zika virus emerged as a global threat, the Walter Reed Army Institute of Research (WRAIR) drew on its deep expertise in protecting soldiers against malaria, Ebola and other flaviviruses, to [Read more]
© 2017 Global Biodefense